Elanco Animal Health Inc

Análisis de la acción Elanco Animal Health Inc (ELAN)

$22.550

+0.140 (+0.62%)Al cierre

Loading chart…
Máximo
22.920
Apertura
22.380
Precio medio ponderado por volumen
22.58
Volumen
4.94M
Capitalización
7.05B
Mínimo
22.265
Importe
111.60M
EV/EBITDA, TTM
12.59

Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.

www.elanco.com

Análisis de IA of Elanco Animal Health Inc (ELAN)

Comprar

Elanco Animal Health Inc is a good buy right now due to its recent positive financial performance and strong insider confidence. The current price is $22.92, and the forward P/E ratio is 17.36, indicating reasonable valuation. Additionally, the gross margin has improved to 48.17% in Q2 2026, showcasing operational efficiency. The main risk is the negative net income reported in Q4 2025, amounting to -$276 million, which investors should monitor closely.

Recomendaciones de analistas (11)

+13.08% de potencial alcista
Mantener
5 Comprar
6 Mantener
0 Vender
Actual: 22.55
Mínimo
22.00
Promedio
25.50
Máximo
30.00

KeyBanc

2026-08-06

Precio objetivo

$30

Sobreponderar

Citi

2026-08-06

Precio objetivo

$34

Comprar

Morgan Stanley

2026-07-22

Precio objetivo

$26

Equal Weight

TD Cowen

2026-06-18

Precio objetivo

$32

Comprar

Morgan Stanley

2026-05-15

Precio objetivo

$23

Equal Weight

Métricas de valoración

El PER previsto actual de Elanco Animal Health Inc (ELAN) es 17.36, frente a su media de 5 años de 17.73.

PER previsto

Valor razonable
Media 5A P/E
17.73
P/E actual
17.36
Sobrevalorada
22.10
Infravalorada
13.36

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
13.65
EV/EBITDA actual
12.59
Sobrevalorada
16.50
Infravalorada
10.80

Precio/ventas previsto

Valor razonable
Media 5A P/S
1.80
P/S actual
2.07
Sobrevalorada
2.37
Infravalorada
1.24

Escenarios de precio de Alphio AI para ELAN

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%ELAN

$13.97

Precio del escenario

B

Base

Base · 50%ELAN

$13.55

Precio del escenario

B

Bajista

Bajista · 25%ELAN

$10.58

Precio del escenario

Ballenas con ELAN en cartera

D

Douglas Lane & Associates, LLC

+ Con en carteraELAN

+4.22%

Rentabilidad a 3 meses

P

PRIMECAP Management Company

+ Con en carteraELAN

+1.77%

Rentabilidad a 3 meses

B

Bowen, Hanes & Company, Inc.

+ Con en carteraELAN

-1.12%

Rentabilidad a 3 meses

Cronología de eventos

2026-08-26 (ET)

09:00:00

Elanco Animal Health Completes 25,000-SF Manufacturing Expansion

2026-08-07 (ET)

15:00:00

Elanco Receives FDA Emergency Authorization for CLiK Extra to Prevent New World Screwworm Infestations

2026-08-05 (ET)

07:00:00

Elanco Animal Health Raises FY26 Revenue Outlook to $5.09B-$5.14B

07:00:00

Elanco Reports Q2 Revenue of $1.37B, Beating Consensus

2026-06-18 (ET)

07:30:00

Elanco Animal Health Establishes Elanco Ventures Investment Platform with $25M Commitment

Noticias

Preguntas frecuentes sobre ELAN, respondidas por Alphio AI

Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Elanco Animal Health Inc is a good buy right now due to its recent positive financial performance and strong insider confidence. The current price is $22.92, and the forward P/E ratio is 17.36, indicating reasonable valuation. Additionally, the gross margin has improved to 48.17% in Q2 2026, showcasing operational efficiency. The main risk is the negative net income reported in Q4 2025, amounting to -$276 million, which investors should monitor closely.

11 analysts cover ELAN: 5 rate it Buy, 6 Hold and 0 Sell. The average price target is 25.50.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar